In anticipation of its presentation at the J.P. Morgan Global Healthcare Conference, obesity drugmaker VIVUS (NASDAQ:VVUS) released its presentation in an SEC filing. Investors were particularly impressed with the improved prescription data for Qsymia, and shares jumped around 8% today on this news. In the following video, health care analyst Max Macaluso discusses this news, reasons for why Qsymia prescriptions are gaining momentum, and what this means for Arena Pharmaceuticals (NASDAQ:ARNA) -- VIVUS' main competitor in the obesity drug market.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.